Boosting B cell and Macrophage‐Mediated Humoral Immunity with Fusion Nanovesicles for Triple‐Negative Breast Cancer Combined Therapy
Yulin Yu,Yang Li,Yinmei Tian,Qian Hu,Xiaonan Li,Jingyao Tu,Han Liu,Conglian Yang,Li Kong,Zhiping Zhang
DOI: https://doi.org/10.1002/adhm.202202209
IF: 10
2022-11-20
Advanced Healthcare Materials
Abstract:Cell‐derived nanovesicles have been widely utilized as therapeutic agents for cancer therapy. Current research mostly focused on their ability to activate antitumor cellular immunity. However, whether they can activate and participate in antitumor humoral immunity was rarely studied. Here, a doxorubicin‐loaded hybrid cell nanovesicles (DNV) were designed for boosting antitumor humoral and cellular immunity. The hybrid cell nanovesicles were generated through fusion of nanovesicles derived from M1‐type macrophages and 4T1 tumor cells. It was found that DNV could accumulate at tumor tissues and draining lymph nodes effectively, which resulted in the activation of antitumor immune response and significant inhibition of tumor progression. During this process, dendritic cells were effectively activated, subsequently inducing cytotoxicity T lymphocytes mediated cellular immunity. Furthermore, DNV elicited the antitumor humoral immunity through boosting T follicular helper cells and germinal center B cells. By analyzing the mechanism behind humoral immunity activation, it was found that M1‐type macrophages repolarized by DNV played an important role. In general, besides antitumor cellular immunity, the proposed hybrid nanovesicles provided a promising strategy for enhancing antitumor humoral immunity by macrophages repolarization and germinal center B cells activation. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials